Pyxis Oncology (PYXS) Stock Price, News & Analysis

Company Overview

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens. The company’s proprietary conjugation technology is intended to optimize drug‐to‐antibody ratios and stability in circulation, enabling more efficient tumor penetration and payload release. While most programs are currently in preclinical or Phase I development, Pyxis’s strategic approach seeks to address cancers that have historically proven resistant to standard treatments, including triple‐negative breast cancer and certain gastrointestinal malignancies.

Headquartered in Boston, Massachusetts, Pyxis Oncology conducts research and clinical activities across the United States, with plans to expand trials into Europe and Asia as programs advance. The organization draws on expertise from seasoned professionals in oncology drug discovery, translational research and clinical development. Pyxis Oncology continues to collaborate with academic institutions and contract research organizations to accelerate its mission of bringing safer, more effective cancer therapies to patients worldwide.

Key Stats

• Today's Range: $1.58 to $1.98
• 50-Day Range: $1.04 to $1.91
• 52-Week Range: $0.83 to $5.39
• Volume: 2.22 million shs
• Average Volume: 545,748 shs
• Market Capitalization: $118.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.75
• Consensus Rating: Moderate Buy

Pyxis Oncology Stock Analysis - MarketRank™

Pyxis Oncology scored higher than 42% of companies evaluated by MarketBeat, and ranked 732nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Pyxis Oncology has a consensus price target of $7.75, representing about 305.8% upside from its current price of $1.91.

Amount of Analyst Coverage

Pyxis Oncology has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Pyxis Oncology are expected to decrease in the coming year, from ($1.04) to ($1.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pyxis Oncology is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pyxis Oncology is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pyxis Oncology has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.40% of the float of Pyxis Oncology has been sold short.

Short Interest Ratio / Days to Cover

Pyxis Oncology has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Pyxis Oncology has recently increased by 7.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pyxis Oncology does not currently pay a dividend.

Dividend Growth

Pyxis Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.40% of the float of Pyxis Oncology has been sold short.

Short Interest Ratio / Days to Cover

Pyxis Oncology has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Pyxis Oncology has recently increased by 7.02%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.34

News Sentiment

Pyxis Oncology has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Pyxis Oncology this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for PYXS on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pyxis Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.60% of the stock of Pyxis Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 39.09% of the stock of Pyxis Oncology is held by institutions.

PYXS Stock Analysis - Frequently Asked Questions

How have PYXS shares performed this year?

Pyxis Oncology's stock was trading at $1.56 at the beginning of 2025. Since then, PYXS shares have increased by 22.4% and is now trading at $1.91.

How were Pyxis Oncology's earnings last quarter?

Pyxis Oncology, Inc. (NASDAQ:PYXS) announced its earnings results on Thursday, August, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The firm earned $2.82 million during the quarter.

When did Pyxis Oncology IPO?

Pyxis Oncology (PYXS) raised $158 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 10,500,000 shares at $14.00-$16.00 per share.

Who are Pyxis Oncology's major shareholders?

Top institutional investors of Pyxis Oncology include Geode Capital Management LLC (0.82%), Pier 88 Investment Partners LLC (0.59%), Jane Street Group LLC (0.54%) and Schulhoff & Co. Inc. (0.44%). Insiders that own company stock include Pfizer Inc, Lara Sullivan, Pamela Ann Connealy and Jitendra Wadhane.
View institutional ownership trends.

How do I buy shares of Pyxis Oncology?

Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pyxis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pyxis Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PYXS
• CIK: 1782223
• Web: www.pyxisoncology.com
• Phone: 617-221-9059
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pyxis Oncology: $7.75
• High Price Target: $13.00
• Low Price Target: $5.00
• Potential Upside/Downside: +305.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$77.33 million
• Net Margins: N/A
• Pretax Margin: -3,481.10%
• Return on Equity: -68.56%
• Return on Assets: -52.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.65
• Quick Ratio: 5.65

Sales & Book Value

• Annual Sales: $16.15 million
• Price / Sales: 7.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.03 per share
• Price / Book: 0.94

Miscellaneous

• Outstanding Shares: 62,020,000
• Free Float: 55,444,000
• Market Cap: $118.46 million
• Optionable: Optionable
• Beta: 1.14